

Information Disclosure Statement Transmittal

Docket Number

RLL-499US

Address To
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

In Re Application Of:

Application No.	10/598,546
Filing Date	June 04, 2007
Examiner	Lori K. MATTISON
Art Unit	1619

Title of Invention

PROCESSES FOR THE PREPARATION OF SOLID DOSAGE FORMS OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE

BASIS FOR FILING (Select 1, 2 or 3 below.)

37 CFR 1.97(b)

- 1) ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53 (d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- 2) ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), but before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

- a) ☒ the statement specified in 37 CFR 1.97(e);

OR

- b) ☐ the fee set forth in 37 CFR 1.17(p).

37 CFR 1.97(d)

- 3) ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(c), and on or before payment of the issue fee, and is accompanied by the Statement as specified in 37 CFR 1.97(e) and the fee set forth in 37 CFR 1.17(p).

Information Disclosure Statement Transmittal

Docket Number

RLL-499US

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The Information Disclosure Statement submitted herewith is submitted under one of the following conditions, which satisfies the requirement under 37 CFR 1.97(e). (Select 4 or 5 below if applicable.)

- 4) ☐ That each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- 5) ☒ That no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Remarks (Enter Remarks Below or Attach Document Containing Remarks)

Fee set forth in 37 CFR 1.17(p):

- ☐ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Information Disclosure Statement Transmittal

Docket Number

RLL-499US

Correspondence Address

Customer Number 26815

-OR-

Name

Address

City

State

Country

Postal Code

Phone Number

E-mail Address

Certificate of Mailing by Express Mail

I hereby certify that this Transmittal Letter, accompanying documents and fee (if appropriate) are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date indicated below:

(Date of Mailing)

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

("Express Mail" Mailing Label Number)

Certificate of Mailing by First Class Mail

I hereby certify that this Transmittal Letter, accompanying documents and fee (if appropriate) are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date indicated below:

(Date of Mailing)

(Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Certificate of Transmission

I hereby certify that this Transmittal Letter, accompanying documents and fee authorization (if appropriate) is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below:

(Date of Transmission)

(Name of Person Transmitting Correspondence)

(Signature of Person Transmitting Correspondence)

Signature Instructions

Select the name of the person who will electronically sign the Transmittal Letter from the drop-down box below.

If a practitioner is not present in the drop-down list, you must close this form and select "Add Practitioner..." in the Form Manager's Utility menu.

Verify that the signatory information is correct and press the 'eSign' button to electronically sign the submission. If you prefer to sign the form manually, simply do not click the 'eSign' button; just print and manually sign.

Signatory Drop-Down Box

James DeYonker, Esq.

Name	James DeYonker	Registration Number	52817
Signatory Capacity	Assignee of record of the entire int	E-mail Address	generalip.mailbox@ranbaxy.com
eSign	/James DeYonker/	Date Signed	07/01/2011